Loading...
•
Jun 30, 2023
Generation Bio Q2 2023 Earnings Report
Generation Bio's financial performance declined in Q2 2023 with reduced R&D spending but increased G&A expenses, while collaboration revenue was recognized.
Key Takeaways
Generation Bio reported a net loss of $31.1 million, or $0.47 per share, for the second quarter of 2023. The company's cash position remains strong at $314.1 million, expected to fund operations into 2025. They are focused on demonstrating Factor VIII expression in non-human primates for hemophilia A program.
Cash, cash equivalents, and marketable securities totaled $314.1 million as of June 30, 2023.
Research and development expenses were $21.8 million for the quarter ended June 30, 2023.
General and administrative expenses were $13.0 million for the quarter ended June 30, 2023.
Net loss was $31.1 million, or $0.47 basic and diluted net loss per share, for the quarter ended June 30, 2023.
Generation Bio
Generation Bio
Generation Bio Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The company is focused on demonstrating Factor VIII expression in non-human primates for its hemophilia A program and continued development of in-vivo targeting to immune cells with its stealth ctLNPs. Its cash position is expected to fund operations into 2025.
Positive Outlook
- Demonstrating Factor VIII expression in non-human primates for hemophilia A program
- Continued development of in-vivo targeting to immune cells with stealth ctLNPs
- Cash position expected to fund operations into 2025